Newsgather
BackSouth Korean Stocks Hit Record High Over 8,000 on Hopes for U.S.-Iran Deal
South Korean Stocks Hit Record High Over 8,000 on Hopes for U.S.-Iran Deal
BREAKING
Yonhap News5/26/2026Business1 min readSouth Korea

South Korean Stocks Hit Record High Over 8,000 on Hopes for U.S.-Iran Deal

Quick Look

  • South Korean stocks surged past 8,000 points to a new record high Tuesday, driven by optimism over potential peace negotiations between the U.S. and Iran, which could reopen the Strait of Hormuz.
  • Oil prices also fell sharply on the news.

AI-generated summary

Font size

SEOUL, May 26 (Yonhap) -- South Korean stocks opened at a new record high of over 8,000 Tuesday on rising hopes for a U.S.-Iran deal to reopen the Strait of Hormuz.

The benchmark Korea Composite Stock Price Index (KOSPI) rose 183.8 points, or 2.34 percent, to 8,031.51 as of 9:15 a.m.

The index topped the 8,000-point mark for the first time since May 15.

Overnight, U.S. President Donald Trump said that peace negotiations with Iran are proceeding "nicely" but warned of fresh attacks if they fail.

On optimism for a possible end of the war, oil prices fell sharply. Brent crude sank 7 percent to US$96, and U.S. West Texas Intermediate futures dropped 6.5 percent to $90.

The South Korean stock market closed Monday in observance of the Buddha's Birthday holiday.

Market bellwether Samsung Electronics rose 2.14 percent, and its chipmaking rival SK hynix jumped 4.22 percent.

Top carmaker Hyundai Motor gained 2.6 percent, and leading battery maker LG Energy Solution added 2.76 percent.

Major shipbuilder Hanwha Ocean shot up 4.17 percent, and pharmaceutical giant Samsung Biologics climbed 1.06 percent.

The Korean won was trading at 1,514.25 won against the U.S. dollar at 9:15 a.m., up 2.15 won from the previous session.

Related Topics

This article was originally published by Yonhap News.

Related Stories

노보 노디스크, '비만치료제' 경쟁업체 일라이릴리 상대 소송 제기
Developing·4 hours ago

노보 노디스크, '비만치료제' 경쟁업체 일라이릴리 상대 소송 제기

노보 노디스크가 뉴저지 연방 지방법원에 일라이릴리를 상대로 비만치료제 비교 광고 중단 및 시정 광고를 요구하는 소송을 제기했다. 노보 노디스크는 일라이릴리가 저용량 위고비와 고용량 젭바운드를 비교해 소비자를 오도했다고 주장하며, 일라이릴리는 자사 광고를 옹호하며 강력히 대응할 것이라고 밝혔다.

연합뉴스
1 min read
More on this topicKOSPI